Loading...
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon, B Strauss, S Whelan, J Leahy, Michael G Woll, P Cowie, F Rothermundt, C Wood, Z Benson, C Ali, N
Seddon, B
Strauss, S
Whelan, J
Leahy, Michael G
Woll, P
Cowie, F
Rothermundt, C
Wood, Z
Benson, C
Ali, N
Citations
Altmetric:
Abstract
For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma.
Description
Date
2017-10
Publisher
Collections
Files
Keywords
Type
Article
Citation
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. 2017, 18 (10):1397-1410 Lancet Oncol